Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 7/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188570 | 1.00 | SLC7A5 (0.43) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL18528367 | 0.78 | SLC7A5 (0.43) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL17234503 | 0.78 | SLC7A5 (0.43) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL18528440 | 0.78 | SLC7A5 (0.43) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL17234504 | 0.78 | SLC7A5 (0.43) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL647206 | 0.76 | SLC7A5 (0.42) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL647205 | 0.76 | SLC7A5 (0.42) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL13413615 | 0.76 | SLC7A5 (0.42) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL13413616 | 0.76 | SLC7A5 (0.42) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL13413617 | 0.76 | SLC7A5 (0.42) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101595-A1 | SYSTEMS AND METHODS FOR MULTI-REAGENT CHEMICAL LABELING OF BIOLOGICAL MOLECULES | CASE WESTERN RESERVE UNIVERSITY | 2024-03-28 | — | — | US | claimed |
| WO-2022170024-A1 | SYSTEMS AND METHODS FOR MULTI-REAGENT CHEMICAL LABELING OF BIOLOGICAL MOLECULES | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-08-11 | — | — | WO | claimed |
| US-20130012690-A1 | METHOD FOR STABILIZATION OF PROTEINS USING NON-NATURAL AMINO ACIDS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2013-01-10 | — | — | US | claimed |
| US-20090221790-A1 | METHOD FOR STABILIZATION OF PROTEINS USING NON-NATURAL AMINO ACIDS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2009-09-03 | — | — | US | claimed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| US-20260001924-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | NEW YORK UNIVERSITY (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4640217-A1 | ANTICANCER AGENT | AGC INC. (JP) | 2025-10-29 | — | — | EP | disclosed |
| US-20250312303-A1 | ANTICANCER AGENT | AGC Inc. (JP) | 2025-10-09 | — | — | US | disclosed |
| US-12371461-B2 | Nemo coiled coil mimics and methods of using same | NEW YORK UNIVERSITY (US) | 2025-07-29 | — | — | US | disclosed |
| EP-3303367-B1 | STABILIZED MINIMAL COILED-COIL MIMETICS | UNIV NEW YORK (US) | 2025-06-18 | — | — | EP | disclosed |
| US-20240410897-A1 | INTACT MASS SPECTROMETRY FOR DIRECT PROTEIN FOOTPRINTING DOSIMETRY USING COVALENT LABELING | CASE WESTERN RESERVE UNIVERSITY | 2024-12-12 | — | — | US | disclosed |
| WO-2024135746-A1 | ANTICANCER AGENT | ＡＧＣ株式会社 | 2024-06-27 | — | — | WO | disclosed |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-30 | — | — | US | disclosed |
| EP-1196436-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001064678-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001040262-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001002424-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-01-11 | — | — | WO | disclosed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0787010-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-06 | — | — | EP | disclosed |
| WO-1996012499-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371461-B2 | Nemo coiled coil mimics and methods of using same | COIL, CALCOCO2, NCAPH | SLC7A5 3871/4885SLC1A3 1986/4885SLC1A2 2121/4885 |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | TMPRSS15, CTRC, CPN1 | SLC7A5 860/4885SLC1A3 2604/4885SLC1A2 3427/4885 |
| US-20260001924-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | DDX21, PHAX, RBX1 | SLC7A5 3352/4885SLC1A3 2255/4885SLC1A2 2731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.